Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Sarcoma, Endometrial Stromal 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Buccal Mucosa Cancer 1Adrenocortical Adenoma 1

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Endometrial Stromal × Postmortem Imaging × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡